PARIS--(BUSINESS WIRE)--StatLife, a medtech company developing disease risk prediction software, has joined forces with the international MyPeBS (My Personal Breast Screening) study. This randomised study, granted by the European Union, aims to recruit 85,000 women aged between 40 and 70 in Europe to evaluate the effectiveness of personalized screening based on each woman's risk of developing breast cancer. Statlife is in charge of the risk assessment.
Valérie Hélin, head of medical affairs at StatLife, said: “We are delighted that Statlife has been selected by the experts at MyPeBS, an international benchmark clinical study, to develop the risk scoring system. For Statlife, this is an important step forward that will help us to make risk scoring – similar to MammoRisk but more complete – an integral part of day-to-day clinical practice, allowing women to receive personalized care with respect to breast cancer screening. Personalized screening could have a major impact on public health, initially by reducing the number of cases in which breast cancer is diagnosed at advanced stages, and eventually by reducing the breast cancer mortality rate.”
About MyPeBS : www.mypebs.eu
About StatLife : http://www.stat.life/home.php
About MammoRisk - https://mammorisk.com
This project has been funded by the European Union as part of the Horizon 2020 research and innovation programme (no. 755394).
